Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Sinema has backed a bill advancing in the Arizona legislature that would include a $5 million grant to a neurological ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

Midi Health, the virtual care company best known for providing hormone therapy for women in menopause, is expanding to ...

Eisai and Merck succeeded in stopping Shilpa Medicare Ltd. from launching a generic version of Lenvima for at least another ...

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...